GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (NAS:VALN) » Definitions » Gross Margin %

VALN (Valneva SE) Gross Margin % : 43.96% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Valneva SE Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Valneva SE's Gross Profit for the three months ended in Sep. 2024 was $22.4 Mil. Valneva SE's Revenue for the three months ended in Sep. 2024 was $50.9 Mil. Therefore, Valneva SE's Gross Margin % for the quarter that ended in Sep. 2024 was 43.96%.

Warning Sign:

Valneva SE gross margin has been in long-term decline. The average rate of decline per year is -20.8%.


The historical rank and industry rank for Valneva SE's Gross Margin % or its related term are showing as below:

VALN' s Gross Margin % Range Over the Past 10 Years
Min: 10.2   Med: 52.18   Max: 60.68
Current: 38.58


During the past 13 years, the highest Gross Margin % of Valneva SE was 60.68%. The lowest was 10.20%. And the median was 52.18%.

VALN's Gross Margin % is ranked worse than
69.61% of 747 companies
in the Biotechnology industry
Industry Median: 60.58 vs VALN: 38.58

Valneva SE had a gross margin of 43.96% for the quarter that ended in Sep. 2024 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Valneva SE was -20.80% per year.


Valneva SE Gross Margin % Historical Data

The historical data trend for Valneva SE's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Gross Margin % Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.18 50.78 46.01 10.20 34.37

Valneva SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.91 37.79 32.34 38.34 43.96

Competitive Comparison of Valneva SE's Gross Margin %

For the Biotechnology subindustry, Valneva SE's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Valneva SE's Gross Margin % falls into.



Valneva SE Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Valneva SE's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=57.6 / 167.625
=(Revenue - Cost of Goods Sold) / Revenue
=(167.625 - 110.006) / 167.625
=34.37 %

Valneva SE's Gross Margin for the quarter that ended in Sep. 2024 is calculated as


Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=22.4 / 50.859
=(Revenue - Cost of Goods Sold) / Revenue
=(50.859 - 28.499) / 50.859
=43.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Valneva SE  (NAS:VALN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Valneva SE had a gross margin of 43.96% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Valneva SE Gross Margin % Related Terms

Thank you for viewing the detailed overview of Valneva SE's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE Business Description

Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Valneva SE Headlines

From GuruFocus

Q3 2020 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2022 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Valneva SE at Jefferies Healthcare Conference Transcript

By GuruFocus Research 02-09-2024

Half Year 2021 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2023 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Valneva SE at Jefferies Healthcare Conference Transcript

By GuruFocus Research 02-09-2024

Q1 2023 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2024 Valneva SE Earnings Call Transcript

By GuruFocus Research 05-08-2024

Valneva SE Annual Shareholders Meeting Transcript

By GuruFocus Research 02-09-2024

Half Year 2023 Valneva SE Earnings Call Transcript

By GuruFocus Research 02-09-2024